Table 1 Baseline characteristics before chemoradiotherapy and salvage endoscopic therapy

Before chemoradiotherapy

P value

Characteristics

Number

%

Number

%

Number

%

Gender

1.000

 Male

74

96.1

37

94.9

37

97.4

 Female

3

3.9

2

5.1

1

2.6

Location

0.509

 Upper

22

28.6

11

28.2

11

28.9

 Middle

41

53.2

19

48.7

22

57.9

 Lower

14

18.2

9

23.1

5

13.2

cT factor

0.271

 1

33

42.9

21

53.8

12

31.6

 2

10

13.0

4

10.3

6

15.8

 3

27

35.1

11

28.2

16

42.1

 4

7

9.1

3

7.7

4

10.5

Lymph node metastasis

0.355

 Absent

47

61.0

26

66.7

21

55.3

 Present

30

39.0

13

33.3

17

44.7

cStage

0.394

 I

27

35.1

17

43.6

10

26.3

 II

27

35.1

13

33.3

14

36.8

 III

16

20.8

6

15.4

10

26.3

 IV

7

9.1

3

7.7

4

10.5

Before salvage endoscopic therapy

P value

Characteristics

Number

%

Number

%

Number

%

Median age (range)

65 (44–84)

63 (44–77)

67 (51–84)

0.038

Chemotherapy regimen

0.716

 Cisplatin + fluoropyrimidine

71

92.2

36

92.3

35

92.1

 Nedaplatin + fluoropyrimidine

3

3.9

2

5.1

1

2.6

 Monotherapy

3

3.9

1

2.6

2

5.3

Radiation dose

0.702

 50.4

29

37.7

13

33.3

16

42.1

 60

43

55.8

23

59.0

20

52.6

  > 60

5

6.5

3

7.7

2

5.3

Tumor depth evaluated with EUS

<0.001

 uT1

67

87.0

39

100.0

28

73.7

 uT2

10

13.0

0

0.0

10

26.3

Circumferential spread

0.002

  < 1/4

45

58.4

30

76.9

15

39.5

 1/4 ≤, < 1/2

27

27.0

6

15.4

21

55.3

 1/2 ≤, < 3/4

4

4.0

2

5.1

2

5.3

 3/4 ≤

1

1.3

1

2.6

0

0.0